Group 1 - The core viewpoint of the news is that Kangwei Century's stock has experienced a decline of 5.09% on September 17, with a total market value of 3.124 billion yuan and a cumulative drop of 3.94% over three consecutive days [1] - Kangwei Century, established on September 3, 2010, specializes in the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales and 10.86% from services [1] - The stock trading volume on the reporting day was 41.74 million yuan, with a turnover rate of 3.87% [1] Group 2 - Among the top ten circulating shareholders of Kangwei Century, a fund under China Europe Fund, specifically the China Europe Times Pioneer Stock A (001938), has entered the list, holding 2 million shares, which accounts for 5.26% of the circulating shares [2] - The fund has incurred a floating loss of approximately 2.98 million yuan today, with a total floating loss of 2.4 million yuan during the three-day decline [2] - The fund manager, Zhou Weiwen, has a tenure of 18 years and 312 days, with a total fund asset scale of 29.38 billion yuan, while the other manager, Luo Jiaming, has a tenure of 6 years and 80 days, managing assets of 13.271 billion yuan [2]

证券代码：688426 证券简称：康为世纪 公告编号：2025-036 江苏康为世纪生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 15 日 （二） 股东大会召开的地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世 纪生物科技股份有限公司 2 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 普通股股东人数 | 33 | | 2、出席会议的股东所持有的表决权数量 | 80,039,900 | | 普通股股东所持有表决权数量 | 80,039,900 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 72.8087% | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

上海市通力律师事务所关于江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致:江苏康为世纪生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏康为世纪生物科技股份有限 公司(以下简称"公司")的委托,指派本所夏青律师、郭珣律师(以下简称"本所律 师")根据《中华人民共和国公司法》《中华人民共和国证券法》等法律、法规以及规 范性文件(以下统称"法律法规")及《江苏康为世纪生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第一次临时股东大会(以下简称"本次股 东大会"）相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中，公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并 ...

Core Viewpoint - 康为世纪 reported a revenue of 87.12 million yuan for the first half of the year, a year-on-year increase of 29.74%, but faced a net loss of 55.91 million yuan, a decrease of 11.70% compared to the previous year, indicating a "revenue growth without profit increase" situation [1][3]. Financial Performance - Revenue for the first half of the year was 87.12 million yuan, up 29.74% year-on-year [1]. - Net profit attributable to shareholders was -55.91 million yuan, down 11.70% year-on-year [1]. - Basic earnings per share were -0.508 yuan, and diluted earnings per share were -0.507 yuan [3]. - The weighted average return on net assets was -3.90%, and the return on net assets after deducting non-recurring gains and losses was -4.64% [3]. - R&D expenses accounted for 46.84% of revenue, down from 68.53% year-on-year [3]. Business Challenges and Strategies - The decline in net profit is attributed to the new technology service business being in a ramp-up phase, leading to higher operating costs than revenue growth [1][4]. - 康为世纪's core products include molecular detection reagents and diagnostic kits, with a focus on the Helicobacter pylori detection kit as a key growth driver [4][5]. - The company is expanding its technology service sector, including gene sequencing and synthesis services, to improve profitability [6]. Market Potential - The market for Helicobacter pylori detection products is projected to reach a sales peak of 1.5 billion yuan by 2030, driven by the need for antibiotic resistance testing [5]. - 康为世纪 is actively working on expanding distribution channels, including partnerships with hospitals and online platforms, to enhance market penetration [5][6]. Financial Position - As of mid-year, the company's cash reserves were 160 million yuan, down 63.39% from 437 million yuan year-on-year [6]. - Accounts receivable amounted to 59.38 million yuan, representing 47.18% of total revenue, with a growth rate exceeding that of revenue [6][7]. - R&D expenses decreased by 11.32% to 41 million yuan, and the number of R&D personnel reduced from 229 to 148 [7].

Group 1 - The stock price of Kangwei Century has increased by 5.23% on September 11, reaching 31.00 CNY per share, with a trading volume of 96.66 million CNY and a turnover rate of 8.51%, resulting in a total market capitalization of 3.487 billion CNY [1] - Kangwei Century's stock has risen for three consecutive days, with a cumulative increase of 20.89% during this period [1] - The company, established on September 3, 2010, specializes in the research, production, and sales of molecular detection products, providing molecular detection services as well [1] Group 2 - According to data, one fund from Shenwan Lingxin has Kangwei Century as a top holding, with a reduction of 12,000 shares in the second quarter, holding 445,600 shares, which accounts for 7.43% of the fund's net value, making it the second-largest holding [2] - The fund, Shenwan Lingxin Medical Pioneer Stock A (005433), has a current scale of 120 million CNY and has achieved a return of 5.11% this year, ranking 3885 out of 4222 in its category [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 56 days, with the best fund return during his tenure being -23.62% and the worst being -24.59% [2]

中信证券股份有限公司 关于江苏康为世纪生物科技股份有限公司 2025 半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏康 为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）首次公开发 行股票并在科创板上市及后续持续督导保荐人，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持 续督导职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 9 月 2 日至 2025 年 9 月 3 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、股东大会及董事会议事规则等公司治理制度、股东大 会及董事会会议材料； （2）查阅公司财务管理、会计核算和 ...

Market Overview - On September 10, the medical device sector declined by 0.6%, with Zhongke Meiling leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Top Gainers in Medical Device Sector - Meihua Medical (301363) closed at 26.50, up 6.98% with a trading volume of 232,100 shares and a turnover of 601 million yuan [1] - Kangwei Century (688426) closed at 29.46, up 6.74% with a trading volume of 57,600 shares and a turnover of 171 million yuan [1] - Mailande (688273) closed at 41.19, up 5.13% with a trading volume of 27,500 shares and a turnover of 112 million yuan [1] Top Losers in Medical Device Sector - Zhongke Meiying (835892) closed at 23.04, down 7.80% with a trading volume of 55,400 shares and a turnover of 130 million yuan [2] - AoJing Medical (688613) closed at 25.42, down 4.40% with a trading volume of 134,700 shares and a turnover of 341 million yuan [2] - Kangzhong Medical (688607) closed at 29.18, down 3.35% with a trading volume of 25,700 shares and a turnover of 75.5 million yuan [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 638 million yuan from institutional investors, while retail investors saw a net inflow of 580 million yuan [2][3] - Major stocks like Meihua Medical had a net inflow of 33.34 million yuan from institutional investors, while retail investors had a net outflow of 12.26 million yuan [3] Summary of Individual Stock Performance - Meihua Medical (301363) had a net inflow of 33.34 million yuan from major investors, but a net outflow of 12.26 million yuan from retail investors [3] - ZhenDe Medical (603301) saw a net inflow of 25.49 million yuan from major investors, while retail investors experienced a net outflow of 34.90 million yuan [3] - Kangwei Century (688426) had a net inflow of 13.83 million yuan from major investors, with a significant net outflow from retail investors [3]

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals [1][4] - The meeting will address the completion of certain fundraising investment projects and the allocation of surplus funds to enhance liquidity [4][5] - The company plans to cancel its supervisory board and amend its articles of association, transferring supervisory responsibilities to the audit committee [6][7] Group 1: Meeting Procedures - Shareholders and their representatives must sign in 30 minutes before the meeting and present necessary identification documents [2] - Only authorized personnel, including shareholders, directors, and invited guests, are allowed to attend the meeting [3] - The meeting will be conducted with strict order, and any disruptive behavior will be addressed by staff [3][4] Group 2: Proposals - Proposal 1: The company intends to allocate surplus funds of 104.7854 million yuan from the "Medical Equipment and Biological Testing Reagent Industrialization Project" to enhance liquidity, having already invested 390.2415 million yuan out of the planned 486.6919 million yuan [5] - Proposal 2: The company proposes to abolish the supervisory board and allow the audit committee to assume its responsibilities, with necessary amendments to the articles of association [6][7] - Proposal 3: The company aims to revise and establish certain internal governance systems to align with the latest regulations and improve operational standards [7]

江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会会议资料 江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会 会议资料 二○二五年九月 江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目录 | 2025 | 年第一次临时股东大会会议须知 3 | | --- | --- | | 2025 | 年第一次临时股东大会会议议程 5 | | 2025 | 年第一次临时股东大会会议议案 6 | | | 议案一《关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金议案》6 | | | 议案二《关于取消监事会、修订<公司章程>及其附件并办理工商变更登记的议案》 . 7 | | | 议案三《关于修订和制定部分公司治理制度的议案》 8 | 2 / 9 江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会会议资料 江苏康为世纪生物科技股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保公司股东大会的正常秩序和议事效率， 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股东大会 规则（2022 年修订）》、 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]